Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia
Journal article published in 2020 by
Neeraj Y. Saini,
David Marin,
Celina Ledesma,
Ruby Delgado,
Gabriela Rondon,
Uday R. Popat 
,
Qaiser Bashir ,
Chitra M. Hosing,
Yago Nieto ,
Amin M. Alousi,
Muzaffar H. Qazilbash,
Stefan O. Ciurea ,
Elizabeth J. Shpall,
Issa F. Khouri,
Hagop M. Kantarjian
and other authors.
,
Qaiser Bashir ,
Chitra M. Hosing,
Yago Nieto ,
Amin M. Alousi,
Muzaffar H. Qazilbash,
Stefan O. Ciurea ,
Elizabeth J. Shpall,
Issa F. Khouri,
Hagop M. Kantarjian
and other authors.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
How to best use tyrosine kinase inhibitors (TKIs) of BCR-ABL after allogeneic stem cell transplantation for Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) is unknown but will almost certainly not be addressed by a definitive randomized trial. Saini and colleagues provide a large body of observational data to reinforce earlier circumstantial evidence favoring prophylactic use of TKIs for at least 2 years posttransplant.